{
    "ticker": "QURE",
    "name": "uniQure N.V.",
    "description": "uniQure N.V. is a leading gene therapy company focused on developing transformative treatments for patients with severe genetic diseases, particularly those affecting the central nervous system. Founded in 1998 and headquartered in Amsterdam, Netherlands, uniQure has pioneered the use of AAV (adeno-associated virus) technology to create innovative gene therapies. The company\u2019s lead product, Zolgensma, is designed to treat spinal muscular atrophy (SMA), a life-threatening genetic disorder. In addition to SMA, uniQure is exploring therapies for hemophilia B, Huntington's disease, and other genetic disorders. With a robust pipeline of product candidates, uniQure aims to address unmet medical needs and improve the quality of life for patients through its groundbreaking work in gene therapy. The company emphasizes the importance of safety and efficacy in its clinical trials, and it collaborates with various academic institutions and industry partners to further its research and development efforts. As a frontrunner in the gene therapy space, uniQure is committed to advancing the field and bringing novel treatments to market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Amsterdam, Netherlands",
    "founded": "1998",
    "website": "https://www.uniqure.com",
    "ceo": "Matthijs C. De Groot",
    "social_media": {
        "twitter": "https://twitter.com/uniQure",
        "linkedin": "https://www.linkedin.com/company/uniqure/"
    },
    "investor_relations": "https://investors.uniqure.com",
    "key_executives": [
        {
            "name": "Matthijs C. De Groot",
            "position": "CEO"
        },
        {
            "name": "Sander van Deventer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "Zolgensma",
                "AMT-061"
            ]
        }
    ],
    "seo": {
        "meta_title": "uniQure N.V. | Pioneering Gene Therapy Solutions",
        "meta_description": "Learn about uniQure N.V., a leader in gene therapy focused on treating severe genetic diseases. Explore their innovative therapies and commitment to patient care.",
        "keywords": [
            "uniQure",
            "Gene Therapy",
            "AAV Technology",
            "Spinal Muscular Atrophy",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is uniQure known for?",
            "answer": "uniQure is known for its pioneering work in gene therapy, particularly for treatments targeting genetic diseases like spinal muscular atrophy."
        },
        {
            "question": "Who is the CEO of uniQure?",
            "answer": "Matthijs C. De Groot is the CEO of uniQure N.V."
        },
        {
            "question": "Where is uniQure headquartered?",
            "answer": "uniQure is headquartered in Amsterdam, Netherlands."
        },
        {
            "question": "What are uniQure's main products?",
            "answer": "uniQure's main products include Zolgensma for spinal muscular atrophy and AMT-061 for hemophilia B."
        },
        {
            "question": "When was uniQure founded?",
            "answer": "uniQure was founded in 1998."
        }
    ],
    "competitors": [
        "BMRN",
        "SGMO",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}